New hope for rare bone marrow cancer: drug duo targets spleen swelling and fatigue
NCT ID NCT07357727
First seen Jan 22, 2026 · Last updated May 22, 2026 · Updated 19 times
Summary
This phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for adults with myelofibrosis, a rare bone marrow cancer. The study enrolls 460 people who have not taken JAK inhibitors before. The main goals are to shrink the enlarged spleen and reduce symptoms like fatigue and night sweats.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS (PMF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGSeoul, Yangcheon Gu, 07985, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 03080, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
-
Novartis Investigative Site
RECRUITINGGenolier, 1272, Switzerland
-
Summit Medical Group
RECRUITINGBerkeley Heights, New Jersey, 07922, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.